Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates
1.4 Forecast calculations
1.5 COVID-19 impact at global level
1.6 Data validation
1.7 Data Sources
1.7.1 Secondary
1.7.1.1 Paid sources
1.7.1.2 Unpaid sources
1.7.2 Primary
Chapter 2 Executive Summary
2.1 Preclinical CRO industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Service trends
2.1.3 End-use trends
2.1.4 Regional trends
Chapter 3 Preclinical CRO Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Increasing R&D expenditure worldwide
3.3.1.2 Growing outsourcing of R&D activities
3.3.1.3 Rising number of drugs in preclinical trails
3.3.2 Industry pitfalls & challenges
3.3.2.1 Stringent regulatory policies
3.4 Growth potential analysis
3.4.1 By service
3.4.2 By end-use
3.5 COVID-19 impact analysis
3.6 Preclinical trial volume analysis
3.6.1 preclinical trial volume analysis, by region, 2018 - 2021
3.6.2 preclinical trial volume analysis, by indication, 2018 - 2021
3.6.3 preclinical trial volume analysis, by phase of development, 2018 - 2021
3.7 Regulatory landscape
3.7.1 U.S.
3.7.2 Europe
3.7.3 Asia Pacific
3.7.3.1 Singapore
3.7.3.2 Malaysia
3.7.3.3 Indonesia
3.7.3.4 Thailand
3.7.3.5 South Korea
3.7.3.6 Philippines
3.8 Clinical trials- Asia Pacific advantage
3.9 Pricing Landscape
3.10 Industry ecosystem analysis
3.11 Drug discovery and development process
3.12 Porter’s analysis
3.13 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Strategic dashboard, 2022
4.5 Merger & acquisition landscape
4.5.1 Merger & acquisition deals in the CRO industry, 2018 – 2022
4.5.2 Completed contract research organization merger & acquisition deals, 2018-2021
4.5.3 Influence of private equity in CRO mergers & acquisitions
4.5.3.1 PRA Health Sciences
4.5.3.2 Medpace, Inc.
4.5.3.3 PPD, Inc.
4.5.3.4 Parexel International Corporation
4.5.4 Impact of industry consolidation on the overall market
4.5.5 Analyst insights
Chapter 5 Preclinical CRO Market, By Service
5.1 Key segment trends
5.2 Bioanalysis & DMPK studies
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Toxicology testing
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Others
5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Preclinical CRO Market, By End-use
6.1 Key segment trends
6.2 Biopharmaceutical companies
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Government and academic institutes
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Medical devices companies
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Others
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Preclinical CRO Devices Market, By Region
7.1 Key regional trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.6 MEA
7.6.1 South Africa
7.6.2 Saudi Arabia
Chapter 8 Company Profiles
8.1 Charles River Laboratory, Inc.
8.2 Laboratory Corporation of America, Inc.
8.3 Pharmaceutical Product Development (PPD), LLC (a part of Thermo Fisher Scientific),
8.4 ICON plc
8.5 Eurofins Scientific
8.6 Parexel International Corporation
8.7 Medpace, Inc.
8.8 WuXi AppTec
8.9 SGS SA
8.10 Altasciences Company, Inc.
